

**John Sculley, Former Pepsi-Cola Co President and  
Former Apple CEO, Joins Flex Pharma's Board of Directors**

September 22, 2014

Boston, MA – Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, today announced the appointment of John Sculley to its Board of Directors. Mr. Sculley will lend his extensive entrepreneurial experience and legendary marketing acumen to Flex Pharma's senior management team.

"I was drawn to join the board of Flex Pharma because the Company's highly lauded scientific founders and experienced management team are developing innovative solutions to relieve painful muscle cramps, which represents a significant market opportunity with broad appeal," said Mr. Sculley. "Flex Pharma epitomizes the type of game-changing health care company that I am motivated to foster with my background and experience."

Mr. Sculley has decades of experience leading major corporations in the consumer beverage and technology sectors, most notably serving as CEO of Apple and President of Pepsi-Cola Co., which owns the Gatorade brand of products. He is a world-renowned business speaker, mentors several serial entrepreneurs and has extensive experience guiding companies as a board member.

"John's entrepreneurial insights will be invaluable to the company as we work to develop solutions for patients with neuromuscular disorders," commented Flex Pharma Co-Founder, Co-Chair of the Company's Scientific Advisory Board and Nobel Laureate, Rod MacKinnon, M.D.

"I am excited to be working with John as he has helped build many successful companies," said Flex Pharma Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. "We are thrilled to have John join the other distinguished members of our Board."

Flex Pharma's Board of Directors also includes Peter Barton Hutt, former General Counsel of the U.S. Food and Drug Administration and Steve Kraus, Partner of Bessemer Venture Partners.

## **About Flex Pharma**

Flex Pharma, Inc. is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders. Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The Company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. Flex Pharma is backed by the Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, LLC and a number of additional blue chip investor funds and angels.

Additional information about Flex Pharma is available online at <http://www.flex-pharma.com>.

Contact:

Elizabeth Woo  
Corporate Communications & Investor Relations  
Flex Pharma, Inc.  
[ewoo@flex-pharma.com](mailto:ewoo@flex-pharma.com)  
617-874-1829